Clinical Research Papers:
Activation of insulin-like growth factor 1 receptor in patients with non-small cell lung cancer
Metrics: PDF 1255 views | HTML 1163 views | ?
Jin-Soo Kim1,5, Edward S. Kim1, Diane Liu2, J. Jack Lee2, Carmen Behrens3, Scott M. Lippman1, Waun Ki Hong1, Ignacio I. Wistuba1,3, Euni Lee4 and Ho-Young Lee4
1 Department of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
2 Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
3 Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
4 College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, Republic of Korea
5 Present address: Department of Internal Medicine, Seoul National University Boramae Medical Center, Seoul, Republic of Korea
Ho-Young Lee, email:
Euni Lee, email:
Keywords: non-small cell lung cancer, insulin-like growth factor-1 receptor, prognosis, tissue microarray
Received: February 23, 2015 Accepted: March 20, 2015 Published: April 12, 2015
According to previous reports demonstrating the implication of insulin-like growth factor receptor (IGF-1R) signaling in non-small cell lung cancer (NSCLC), in this study, the potential prognostic values of IGF-1R expression/activation were analyzed. The expression and activation of IGF-1R were evaluated in two tissue microarray (TMA) sets from NSCLC patients (N = 352 for TMA I, and N = 353 for TMA II). Alterations in IGF-1R protein or mRNA expression in NSCLC patients were evaluated using publicly available data from The Cancer Genome Atlas (TCGA). We found that membranous and cytoplasmic IGF-1R expressions were significantly associated with squamous cell carcinoma (SCC) in both of the TMAs. Analysis of the TCGA data revealed increased mRNA levels in NSCLC patients, which was significantly associated with reductions in overall survival (OS) (median survival 26.51 vs. 47.77 months, P = 0.017) and disease-free survival (median survival 17.44 vs. 37.65 months, P = 0.045) only in NSCLC patients with adenocarcinoma (ADC). These data suggest that IGF-1R is activated in patients with NSCLC, particularly those with SCC. IGF-1R mRNA expression is a potential prognostic factor in patients with NSCLC, especially those with ADC. Further studies are warranted to investigate the prognostic value of IGF-1R in NSCLC patients.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.